SELLAS Life Sciences’ shares sold off after a sharp decline in public pricing—without a corresponding issuer filing or company update—highlighting how timing around its Phase 3 REGAL trial can move sentiment ahead of topline results. The company remains blinded as it waits for the 80 prespecified events required to complete database lock in galinpepimut-S (GPS) maintenance therapy for acute myeloid leukemia patients in second complete remission.